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i.org/1asymptomatic recreational athletes. It is unclearwhether exercise-induced cTn releasemirrors a
physiological or pathological underlying process. The aim of this study was to provide a direct
comparison of the release kinetics of high-sensitivity cTnI (hs-cTnI) and T (hs-cTnT) after
endurance-type exercise. In addition, the effect of remote ischemic preconditioning (RIPC), a
cardioprotective strategy that limits ischemia-reperfusion injury, was investigated in a ran-
domized controlled crossover manner. Twenty-ﬁve healthy volunteers completed an outdoor
30-km running trial preceded by RIPC (43 5 min 220 mmHg unilateral occlusion) or control
intervention. hs-cTnT, hs-cTnI, and sensitive cTnI (s-cTnI) concentrations were examined
before, immediately after, 2 and5hoursafter the trial.The completionofa30-kmrun resulted in
a signiﬁcant increase in circulating cTn (time: all p <0.001), with maximum hs-cTnT, hs-cTnI,
and s-cTnI levels of 47 – 27, 69 – 62, and 82 – 64 ng/L (mean – SD), respectively. Maximum
hs-cTnT concentrations were measured in 60% of the participants at 2 hours after exercise,
compared withmaximumhs-cTnI and s-cTnI concentrations at 5 hours in 84% and 80% of the
participants. Application of an RIPC stimulus did not reduce exercise-induced cTn release
(time 3 trial: all p >0.5). In conclusion, in contrast to acute myocardial infarction, maximum
hs-cTnT levels after exercise precede maximum hs-cTnI levels. Distinct release kinetics of
hs-cTnT and hs-cTnI and the absence of an effect of RIPC favors the concept that exercise-
induced cTn release may be mechanistically distinct from cTn release in acute myocardial
infarction.  2016 Elsevier Inc. All rights reserved. (Am J Cardiol 2016;118:281e287)Insight into the (patho)physiology of exercise-induced
cardiac troponin (cTn) release is an active and relevant
topic of discussion.1 The recent advent of both af Clinical Chemistry, bCardiovascular Research Institute
rtment of Cardiology, fDepartment of Pathology, gDe-
al Medicine, Laboratory for Metabolism and Vascular
epartment of Human Movement Sciences, School for
logy and Metabolism, Maastricht University Medical
, the Netherlands; dDepartment of Clinical Chemistry and
tology, Gelre ziekenhuizen, Apeldoorn/Zutphen, the
eDepartment of Clinical Chemistry and Hematology,
al Center, Sittard-Geleen, the Netherlands. Manuscript
, 2016; revised manuscript received and accepted April
s supported by a research grant from Stichting De Wei-
t, the Netherlands) to Prof. van Dieijen-Visser. Abbott
eckman Coulter provided troponin I assays to Prof. van
Dr. Meex. The sponsors had no role in the design and
dy, in the collection, analysis, and interpretation of the
paration, review or approval of the manuscript and the
the manuscript for publication.
for disclosure information.
g author: Tel: (þ31) 43-3874709; fax: (þ31) 43-
s: steven.meex@mumc.nl (S.J.R. Meex).
see front matter  2016 Elsevier Inc. All rights reserved.
0.1016/j.amjcard.2016.04.030high-sensitivity (hs-) assay for cTnI (cTnI) and T (cTnT)
with similar analytical characteristics enables to directly
compare the kinetics of both diagnostic equivalent mole-
cules. For example in acute myocardial infarction (AMI),
where cTn release results from the breakdown of the con-
tractile apparatus after ischemic myocardial injury, peak
levels of hs-cTnI and hs-cTnT are reached at similar levels
after admission.2,3 A direct comparison of exercise-induced
hs-cTnI and hs-cTnT release could provide more insight into
the underlying (patho)physiology. In addition, remote
ischemic preconditioning (RIPC), a powerful noninvasive
cardioprotective strategy, can be applied to study the
contribution of an imbalance between oxygen supply and
demand in exercise-induced cTn release. RIPC describes the
application of brief episodes of nonlethal ischemia and
reperfusion to a tissue or an organ, resulting in protection of
the same or another visceral organ against an injurious
ischemic insult in the future.4 In line with the car-
dioprotective effect of RIPC in various settings of tissue
ischemia, we hypothesize that if an oxygen demand-supply
imbalance contributes to exercise-induced cTn release,
application of an RIPC stimulus would result in reduced
postexercise cTn levels. The aim of this study was a head-
to-head comparison of the release kinetics of hs-cTnT and
hs-cTnI after prolonged endurance-type exercise. Inwww.ajconline.org
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induced cTn release using a randomized controlled single-
blind crossover design.
Methods
Twenty-nine healthy runners (age range 18 to 65 years)
were recruited with posters at local running clubs. Before
testing, all participants were informed about the study pro-
cedures and method but remained naïve to the study ratio-
nale. This study was carried out according to the principles
of the Declaration of Helsinki and approved by the local
Institutional Review Board and Ethics Committee of
Maastricht University Medical Center. All subjects provided
written informed consent before participation. This study
was conducted from March 2013 to June 2013 and was
registered at clinicaltrials.gov as NCT01774461.
In a randomized controlled single-blind crossover design,
participants completed 2 identical outdoor 30-km running
trials, either preceded by an RIPC or control intervention.
Both experimental test days started in the morning and were
separated by at least 2 weeks. Before each trial, participants
were instructed to refrain from any strenuous physical labor
and sports activities for 24 hours and to standardize their
breakfast on both experimental days. The running trials
were organized in a research setting on paved (bicycle) lanes
with a minimal number of cross sections with the start and
ﬁnish z 1 km from Maastricht University Medical Center.
While running, participants were individually followed by a
researcher on a bicycle and allowed to drink water and
Isostar sports drink ad libitum. Before the ﬁrst running trial,
a comprehensive 2-dimensional and 3-dimensional trans-
thoratic echocardiogram at rest was recorded from all par-
ticipants. No abnormalities were observed.
Temporal unilateral upper arm ischemia was achieved by
inﬂating a blood pressure cuff to 220 mm Hg. Circulatory
occlusion lasted 5 minutes and was followed by 5 minutes
of reperfusion by deﬂation of the cuff. This sequence was
repeated for a total of 4 cycles and resulted in a total pro-
cedure time of 40 minutes (4  [5 minutes of circulatory
occlusion þ 5 minutes of nonocclusion]). The control
intervention followed an identical protocol, except for the
blood pressure cuff being inﬂated to only 20 mm Hg,
allowing uninterrupted perfusion. The order of testing
(RIPC vs control) was randomized and counterbalanced
between participants.
Blood samples were collected in serum and
ethylenediaminetetraacetic acid-containing tubes at baseline
(preceding the RIPC intervention), immediately after
exercise, 2 and 5 hours after exercise. Within 1 hour of
collection, hematology parameters were analyzed on a
Sysmex XE-5000 (Kobe, Japan) analyzer. In addition,
serum tubes were centrifuged, and aliquots were stored
at 80C until analysis. Serum cTnT was measured using
the high-sensitivity assay of Roche Diagnostics (Basel,
Switzerland); the clinical reference limit (99th percentile of
a healthy reference population) is 14 ng/L, with a 10%
analytical variation at 13 ng/L.5 Serum cTnI was measured
with the following 2 assays: the STAT high-sensitive
troponin I assay (Abbott Diagnostics, Abbott Park, IL)
and the Access AccuTnIþ3 assay (Beckman Coulter, Brea,CA) According to the package insert, the 99th percentile
limit of the Abbott hs-cTnI assay is 26.2 ng/L with a cor-
responding coefﬁcient of variation of 4%. The Beckman
Coulter assay has a 99th percentile limit of 40 ng/L and a
corresponding 10% imprecision, as speciﬁed by the manu-
facturer. Complementary cardiovascular or skeletal bio-
markers; N-terminal proeB-type natriuretic peptide
(NTproBNP), creatine kinase (CK), CK muscle and brain
fraction (CK-MB), and lactate dehydrogenase were
measured using assays of Roche Diagnostics. In addition,
creatinine (Roche Diagnostics) and cystatin C (Gentian,
Moss, Norway) were measured to calculate the estimated
glomerular ﬁltration rate according to the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) formula.6
Sample size estimation was based on hs-cTnT as the
primary outcome variable. We aimed to include 29 runners
to detect a 30% reduction in exercise-induced hs-cTnT
release due to RIPC (from 40  32 ng/L to 28  32 ng/L,
mean  SD) with a statistical power of 0.8 at an alpha error
probability of 0.05. An estimated postexercise hs-cTnT
concentration of 40 ng/L was based on our previous
studies of marathon-induced hs-cTnT release.7,8 The ex-
pected effect size of 30% was derived from the reports,
where a 40% reduction of cTn release by RIPC preceding
cardiac and vascular surgery has been observed.9e11
Assuming a similar effect in endurance-type exercise, we
considered that a <30% reduction would exclude a relevant
contribution of ischemia-reperfusion in the setting of
exercise-induced cTn release.
Data are presented as mean  SD. A 2-factor (time 
trial) repeated-measures general model was used to assess
difference in biochemical parameters. In addition, trial order
(control or RIPC intervention) was entered into the statis-
tical model as a between-subject variable, partitioning out
this source of variability (analyses not shown). In the case of
a nonnormal distribution, data were transformed by natural
logarithm. All statistical tests were 2-tailed, and a p value of
<0.05 was considered statistically signiﬁcant. Analyses
were performed using IBM SPSS Statistics for Windows
22.0 (IBM Corp, Armonk, NY).
Results
Twenty-nine participants (23 men and 6 women) were
included in the study. Three male participants left the study
prematurely due to a sports-related injury (n ¼ 2) or medical
reason unrelated to the study protocol (n ¼ 1) and were
therefore not included in the analysis. One male participant
was excluded after study completion because of highly
elevated hs-cTnT (Roche), hs-cTnI (Abbott), and sensitive
cTnI (s-cTnI, Beckman) concentrations (72, 316, and
332 ng/L, respectively) before his second running trial. In
the absence of clinical symptoms, these values were highly
suggestive for exercise-induced troponin release in the past
24 hours and hence indicative for noncompliance to a crit-
ical aspect of the study protocol (refrainment of exercise in
the 24 hours preceding the run). Therefore, 25 participants
(19 men and 6 women) with an age of 40  13 years (mean
 SD) were included in the present analysis (Table 1).
Subjects were moderately to highly trained, with an average
of 52 running kilometers per week (range: 20 to 120).
Table 1
Participants characteristics (n ¼ 25)
Variable Subjects’ characteristics
Men 19 (76%)
Age (years) 40  13
Body mass index (kg/m2) 22 (18-25)
Physical activity (h/week) 7 (2-17)
Running activity (km/week) 52 (20-120)
Running experience (years) 10 (2-30)
Marathon or ultra-distance experience 14 (56%)
Data are presented as n (%), mean  SD or mean (range).
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ultradistance trial. None of the subjects had a history of
cardiovascular disease, assessed by medical questionnaire.
The exercise trials were separated by a median of
2 weeks (range: 2 to 7). All participants completed both
trials within a time span of 1:57:13 to 3:13:36 (hours:mi-
nutes:seconds), without symptoms of myocardial ischemia.
There was no difference in the completion time between the
control trial and the trial preceded by ischemic pre-
conditioning: mean control trial 2:26:56 and mean RIPC
trial 2:26:54. The overall average timeframe between the
intervention and the 30-km run was 24 minutes (range: 15 to
41) and similar in the setting with and without RIPC. The
overall average delay from ﬁnish to the ﬁrst postexercise
blood sample collection was 23 minutes (range: 14 to 33)
with no differences in the setting with and without RIPC.
At baseline of the control trial, almost all athletes dis-
played hs-cTnT, hs-cTnI, and s-cTnI concentrations below
the clinical decision limit of myocardial infarction (24, 23,
and 24 participants, respectively; Figure 1). The completion
of a 30-km run resulted in an expected signiﬁcant increase
of circulating hs-cTnT, hs-cTnI, and s-cTnI (time: all
p <0.001; Figure 1, Table 2, Supplementary Figure 1).
Maximum concentrations of hs-cTnT, hs-cTnI, and s-cTnI
were 47  27 ng/L, 69  62 ng/L, and 82  64 ng/L (mean
 SD, control trial) and exceeded the clinical reference
value of hs-cTnT, hs-cTnI, and s-cTnI in 100% (n ¼ 24),
60% (n ¼ 15), and 68% (n ¼ 17) of the participants. The
kinetics of hs-cTnT was different from hs-cTnI and s-cTnI,
as 60% of the participants (n ¼ 15) displayed hs-cTnT
maximum concentrations at 2 hours after exercise,
whereas maximum concentrations of hs-cTnI and s-cTnI
were measured at 5 hours after exercise in 84% and 80%
participants (n ¼ 21 and n ¼ 20), respectively. Elevations of
hs-cTnT, hs-cTnI, and s-cTnI measured immediately after
exercise in the control trial were signiﬁcantly correlated with
each other (Pearson: all R >0.8, p <0.001). In addition,
NTproBNP concentrations increased signiﬁcantly after the
30-km run with maximum concentrations of 14  8 pmol/L
(mean  SD, control trial, time: p <0.001; Figure 1,
Table 2, Supplementary Figure 2). Elevations of NTproBNP
were not signiﬁcantly associated with hs-cTnT, hs-cTnI, or
s-cTnI (Pearson: all R <0.2, p >0.3).
Application of an RIPC stimulus by 4 cycles of 5-minute
blood pressure cuff inﬂation followed by 5 minutes of
deﬂation did not reduce exercise-induced cTn release at 0, 2,
and 5 hours after exercise (Figure 1, Table 2). Similar resultswere obtained when correcting for plasma volume changes
(Supplementary Figure 3). The inclusion of trial order and
age of the participants in the model did not affect the results
(analyses not shown). In addition, exercise-induced changes
of NTproBNP, CK, CK-MB, lactate dehydrogenase, and
estimated glomerular ﬁltration rate did not differ between
the control and RIPC trial (time  trial: all p >0.1, Table 2).
Discussion
The present study provides a direct comparison of the
release kinetics of hs-cTnT and hs-cTnI after prolonged
endurance-type exercise. By serial sampling after exercise,
we demonstrate that hs-cTnT levels peak earlier than hs-
cTnI levels. Furthermore, we show that RIPC, a powerful
noninvasive cardioprotective strategy in the setting of
ischemia-induced cTn release, has no effect on exercise-
induced cTn release.
Recreational running and the participation in long-
distance running events, such as (half-) marathons has
increased tremendously in recent years. Although the car-
diovascular beneﬁts of regular physical exercise are widely
established, it is unclear whether this linear doseebeneﬁt
response relation is present among the whole spectrum from
regular physical exercise to strenuous (ultra) endur-
anceetype exercise.12 An important issue in this intense
scientiﬁc debate is the phenomenon of exercise-induced cTn
release. This is the ﬁrst study that measures the release ki-
netics of both hs-cTnT and hs-cTnI after prolonged
endurance-type exercise. In most of the participants,
maximum concentrations of hs-cTnT, hs-cTnI, and s-cTnI
exceeded the clinical reference value. As cTnT and cTnI are
biologically equivalent for the diagnosis of AMI,13,14 we
observed high correlations between all cTn concentrations
immediately measured after exercise. However, we
demonstrate that hs-cTnT displays maximum concentrations
at an earlier stage after exercise compared with hs-cTnI (2
hours vs >5 hours, respectively). This observation is distinct
from cTn release resulting from the breakdown of the con-
tractile apparatus after ischemic myocardial injury, where
peak levels of hs-cTnT and hs-cTnI are reached within the
same time line after hospital admission, followed by cTn
elevations for over several days after the onset of myocar-
dial ischemia.2,3 Although cTnI and cTnT are different
molecules measured with different assays, we observed that
median maximum postexercise hs-cTnI concentrations were
numerically in the same range of hs-cTnT levels (69 ng/L
and 47 ng/L, respectively). Remarkably, these concentra-
tions are distinct from cTn release in patients with AMI,
where hs-cTnI levels have been measured in multiples of
hs-cTnT (range of multiple of hs-cTnI levels compared with
hs-cTnT: 3.4 to 12.4).2,15,16 All together, these observations
suggest that exercise-induced cTn release may be
mechanistically distinct from irreversible cardiomyocyte
injury in AMI.
An aim of this study was to assess the effect of RIPC on
exercise-induced cardiac biomarker release. The car-
dioprotective effect of RIPC has initially been studied in
single-center studies of patients undergoing cardiac surgery
or angioplasty. Application of RIPC has been shown to
signiﬁcantly reduce postintervention cTn release, which
Figure 1. Release of cardiac biomarkers induced by a 30-km run preceded by a control (closed circles) or RIPC (open circles) intervention. Depicted are the
overall and individual concentrations of hs-cTnT (A), hs-cTnI (B), s-cTnI (C), and NTproBNP (D). Overall concentrations are presented as mean  SEM. The
dotted line represents the clinical reference value of 14 ng/L (hs-cTnT), 26.2 ng/L (hs-cTnI), and 40 ng/L (s-cTnI).
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Table 2
Release of cardiac and skeletal biomarkers induced by a 30-km run preceded by a control or remote ischemic preconditioning intervention
Parameter Pre-exercise 0h post-exercise 2h post-exercise 5h post-exercise P-value
hs-cTnT Roche (ng/L) Time: p <0.001
Control 6  4 37  22 45  26 40  24 Trial: p¼0.2
RIPC 6  3 32  25 42  31 37  26 Time x Trial: p¼0.5
hs-cTnI Abbott (ng/L) Time: p<0.001
Control 6  13 30  28 49  42 67  61 Trial: p¼0.4
RIPC 4  10 31  51 53  78 71  90 Time x Trial: p¼0.5
s-cTnI Beckman (ng/L) Time: p<0.001
Control 5  14 37  33 60  47 80  63 Trial: p¼0.2
RIPC 4  10 33  53 68  104 87  110 Time x Trial: p¼0.7
NTproBNP (pmol/L) Time: p<0.001
Control 4  4 14  9 11  7 11  6 Trial: p¼0.1
RIPC 3  3 11  5 9  5 9  4 Time x Trial: p¼0.1
CK (U/L) Time: p<0.001
Control 144  88 267  125 314  127 423  185 Trial: p¼0.9
RIPC 129  81 264  132 323  167 505  300 Time x Trial: p¼0.1
CK-MB (mg/L) Time: p<0.001
Control 4  3 6  3 7  3 10  5 Trial: p¼0.9
RIPC 4  2 6  3 8  4 12  7 Time x Trial: p¼0.2
LD (U/L) Time: p<0.001
Control 173  26 274  60 259  51 252  45 Trial: p¼0.5
RIPC 167  21 276  63 262  58 249  48 Time x Trial: p ¼0.2
eGFR (mL/min/1.73 m2) Time: p<0.001
Control 110  12 79  16 94  15 103  13 Trial: p ¼0.4
RIPC 108  12 79  20 93  20 100  18 Time x Trial: p¼0.6
Data are presented as mean  SD.
CK ¼ creatine kinase; CK-MB ¼ creatine kinase muscle and brain fraction; eGFR ¼ estimated glomerular ﬁltration rate; hs-cTnT ¼ high-sensitivity cardiac
troponin T; hs-cTnI ¼ high-sensitivity cardiac troponin I; LD ¼ lactate dehydrogenase; NTproBNP ¼ N-terminal proeB-type natriuretic peptide; s-cTnI ¼
sensitive cardiac troponin I; RIPC ¼ remote ischemic preconditioning.
Miscellaneous/Exercise-Induced Cardiac Troponin Release 285further translated into an improvement in all-cause mortal-
ity.17,18 The exact signaling cascade of RIPC is the subject
of intense research, but it is evident that the mediator trig-
gers protection ubiquitously in all visceral organs, by the
activation of cryoprotective signaling.4 However, this
beneﬁcial result of RIPC was not observed in 2 recent large-
scaled multicenter studies of RIPC, which could be related
to a greater number of cardiovascular risk factors and
medications in the clinical setting than in patients in the
pilot studies.19,20 We observed no effect of an RIPC stim-
ulus preceding an endurance-type exercise trial on the ki-
netics of hs-cTnT, hs-cTnI, s-cTnI, and other cardiac or
skeletal biomarkers. By the time this study was conducted,
a study was published where also no effect of RIPC on hs-
cTnI levels induced by a cycling exercise trial was
observed.21 However, no direct comparison of cTnT and
cTnI kinetics was performed. In the present study, we
applied running as the exercise model and measured both
hs-cTnT and hs-cTnI kinetics. Taken together, these ﬁnd-
ings demonstrate that RIPC has no effect on exercise-
induced cTn release.
The biological mechanism underlying exercise-induced
cTn release remains unclear, and there is currently limited
evidence for a speciﬁc mechanism. Several other theories
involving the altered environment of cardiomyocytes have
been suggested, such as stimulation of integrins related to
myocardial stretch or the formation of free oxygen radicals.
Similar to ﬁndings in the literature, we observed no signif-
icant correlation between NTproBNP concentrationsimmediately after exercise and hs-cTnT, hs-cTnI, or s-
cTnI,22,23 which does not provide strong evidence for the
contribution of myocardial stretch in exercise-induced cTn
release. In addition, the role of free oxygen radicals as
contributing mechanism is lacking due to the observations
that antioxidant supplementation had no effect on exercise-
induced cTn release.24
Endurance-type exercise training stimulates physiolog-
ical cardiac adaptations that facilitate appropriate increases
in cardiac output during exercise. For example, endurance-
trained subjects exhibit mostly eccentric hypertrophy,
which is characterized by dilatation of the cardiac chambers
and an increase in the maximal wall thickness.25 The inverse
association of training status with postexercise concentra-
tions of cTn,7,26 as well as an increase in baseline and
postexercise cTn after an endurance training program,27
suggest that elevations of cTn may be linked to structural
and functional cardiac adaptations in response to endurance-
type exercise. However, this relation between biochemical
and functional cardiac changes after endurance-type exer-
cise is currently unclear.
Although our acute ﬁndings of endurance-type exercise
suggest that the underlying mechanism may be different
from irreversible cardiomyocyte injury in AMI, ﬁndings of
subclinical coronary artery disease, right ventricular
ﬁbrotic lesions and right ventricular arrhythmias have been
observed among extensively trained (veteran)
athletes.28e30 The susceptibility of individual athletes to
these injurious effects of strenuous exercise is not fully
286 The American Journal of Cardiology (www.ajconline.org)understood, and the role of exercise-induced hs-cTnT and
hs-cTnI kinetics in the risk stratiﬁcation of individual
athletes is unclear.Acknowledgment: The authors gratefully acknowledge the
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